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Abstract: Prostate cancer is the second leading cause of cancer death in men in the US and 
Europe. The treatment of advanced-stage prostate cancer has been androgen deprivation. Medical 
castration leads to decreased production of testosterone and dihydrotestosterone by the testes, 
but adrenal glands and even prostate cancer tissue continue to produce androgens, which eventu-
ally leads to continued prostate cancer growth despite castrate level of androgens. This stage is 
known as castrate-resistant prostate cancer (CRPC), which continues to be a challenge to treat. 
Addition of androgen antagonists to hormonal deprivation has been successful in lowering 
the prostate-specific antigen levels further, but has not actually translated into life-prolonging 
options. The results of several contemporary studies have continued to demonstrate activation 
of the androgen receptor as being the key factor in the continued growth of prostate cancer. 
Blockade of androgen production by nongonadal sources has led to clinical benefit in this 
  setting. One such agent is abiraterone acetate, which significantly reduces androgen production 
by blocking the enzyme, cytochrome P450 17 alpha-hydroxylase (CYP17). This has provided 
physicians with another treatment option for patients with CRPC. The landscape for prostate 
cancer treatment has changed with the approval of cabazitaxel, sipuleucel-T and abiraterone. 
Here we provide an overview of abiraterone acetate, its mechanism of action, and its potential 
place for therapy in CRPC.
Keywords: CRPC, abiraterone, CYP17, inhibitors, androgens, castration resistant prostate 
cancer
Introduction
Prostate cancer is widely known to be dependent on androgens. The testes secrete 
testosterone which accounts for 95% of androgens in the body while the remainder 
is produced in the adrenal glands.1,2 The majority of testosterone is primarily bound 
to albumin and sex hormone binding globulin, though some is transported as free 
testosterone in serum. Upon entering the testes, free testosterone is converted to 
dihydrotestosterone by the enzyme 5α-reductase. Dihydrotestosterone has a five-fold 
affinity for the androgen receptor compared with testosterone. Prostate cancer growth 
is dependent on levels of androgen in the body which help maintain the balance in 
favor of cell growth over apoptosis.3 Recently, the treatment of CRPC has changed 
dramatically with the approval of sipuleucel-T, cabazitaxel, denosumab, and abirater-
one acetate by the US Food and Drug Administration.
Cabazitaxel is a semisynthetic taxane analog designed to overcome taxane 
r  esistance. Preclinical studies demonstrated cabazitaxel to overcome docetaxel-resistant 
cell lines. Phase I studies further demonstrated cabazitaxel to show efficacy not only 
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in chemotherapy-naïve CRPC but also docetaxel-pretreated 
CRPC. Based on the encouraging results, a Phase III trial 
was designed whereby 755 docetaxel pretreated patients were 
randomized to cabazitaxel plus prednisone every three weeks 
versus mitoxantrone plus prednisone arms every three weeks 
for 10 cycles. Patients in the cabazitaxel arm demonstrated 
a survival benefit of 15.1 months versus 12.7 months in the 
cabazitaxel arm. The Food and Drug Administration has 
approved cabazitaxel for the treatment of prostate cancer.4
Sipuleucel-T is an autologous immunotherapy which was 
approved by the Food and Drug Administration recently for 
treatment of metastatic CRPC. Sipuleucel-T is prepared by 
removing mononuclear cells, including antigen-presenting 
cells by therapeutic leukopheresis and incubating them 
with a combination of cytokines (granulocyte-macrophage 
colony-stimulating factor) and prostatic acid phosphatase. 
Patients undergo leukapheresis at 0, 2, and, 4 weeks with 
reintroduction of the vaccine 2 days later. A Phase III trial of 
sipuleucel-T versus placebo in symptomatic or mildly symp-
tomatic metastatic CRPC demonstrated an overall survival 
benefit of 4.1 months in the sipuleucel-T arm and a 3-year 
overall survival of 31.7% in the sipuleucel-T arm versus a 
23% survival in the placebo arm, though rates of objective 
and prostate-specific antigen responses were very low.5
Androgen receptor and signaling
Androgen signaling is mediated through the androgen receptor, 
a ligand-dependent transcription factor located on the X 
chromosome. The receptor is composed of an amino terminal 
activating domain, a carboxy-terminal ligand   binding domain, 
a hinge region, and a DNA binding domain. The inactive form 
of the androgen receptor resides within the cytoplasm and 
remains bound to heat shock proteins that prevent androgen 
receptor activation. The binding of androgens to the receptor 
leads to dissociation of the heat shock proteins and receptor 
phosphorylation which, in turn, leads to nuclear translocation, 
allowing for transcription of androgen-dependent genes.6
A number of different mechanisms appear responsible 
for castration resistance in prostate cancer. One of them is 
an androgen receptor mutation which is seen occasionally 
in advanced disease.7 Some androgen receptor mutations 
in CRPC make the androgen receptor lose its specificity 
to androgens and it becomes more responsive to estrogens, 
progesterone, and even antiandrogens.8 This can lead to 
prostate cancer growth despite castrate levels of testosterone. 
Occasionally, prostate cancer with resistance to flutamide 
will still respond to other antiandrogens like bicalutamide, 
suggesting that mutations in the androgen receptor are a 
direct result of selective pressure.9 Androgen receptor hyper-
responsiveness can also result from androgen receptor gene 
amplification. Copy number gains of the androgen receptor 
allow continued prostate cancer growth despite low androgen 
levels. Androgen receptor gene amplifications are noted in 
28% of recurrent therapy-resistant prostate cancer patients 
exposed to androgen ablation, but has not been observed in 
early tumor samples without exposure to androgen ablation.10 
This suggests the possibility of clonal selection of cancer cells 
with the ability to grow despite very low levels of circulating 
androgens. Upregulation of nuclear transcription coactivators 
also allows androgen receptor-mediated gene transcription 
despite low levels of circulating androgens or presence of 
less potent androgens.11 In addition, prostate cancer cells 
have been shown to upregulate intratumoral steroidogenesis 
to maintain intratumor androgen at levels required for tumor 
growth.12 This mechanism leads to tumor growth despite 
castrate level androgens in the body. In addition, the fusion 
of androgen-activated TMPRSS2 with the ETS family of 
oncogenes ERG or ETV1 has been noted to occur frequently 
in prostate cancer. The precise role of TMPRSS2/ETS 
translocations in castration resistance is unclear at this time, 
although androgen-regulated ERG transcription is reactivated 
in the setting of androgen receptor reactivation in castration 
resistance, and may contribute to progression of CRPC.13
Cytochrome P17 enzyme
The CYP17 enzyme is a cytochrome P450 (CYP) enzyme. 
Located in the endoplasmic reticulum of the testis,   ovaries, 
adrenals, and placenta, CYP17 drives the synthesis of 
  glucocorticoids and sex hormones. The enzyme has both 17α 
hydroxylase and C17,20 lyase activity, and plays a   critical role in 
the production of cortisol and   androgen synthesis (Figure 1). 
Cytochrome b5 regulates the   activity of CYP17,20 lyase. A high 
b5/CYP 17,20 lyase ratio   usually occurs in the testes, which 
leads to production of   androgens, while a low b5/c lyase ratio 
in adrenal glands will ensure cortisol production.14,15
Role in androgen production
Production of androgens or cortisol in the body begins by 
conversion of cholesterol into pregnenolone which can 
then be further converted to androgens or progesterone 
via 3β hydroxysteroid dehydrogenase. 17α hydroxylase 
then converts progesterone into 17α hydroxyprogester-
one and pregnenolone into 17α hydroxypregnenolone. 
C17,20 lyase then converts 17α hydroxyprogesterone and 
17α hydroxyp  regnenolone into androstenedione and 
de  hydroepiandrosterone, respectively. Androstenedione 
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and dehydroepiandrosterone are eventually converted 
into te  stosterone by enzymatic pathways. The enzyme 5α 
reductase then converts testosterone into dihydrotestosterone. 
Abiraterone inhibits C17,20 lyase irreversibly.
Role in cortisol production
17α hydroxypregnenolone and 17α hydroxyprogesterone 
are also converted to cortisol precursors.   Adrenocorticotropic 
hormone (ACTH) acts as a stimulus for converting 
  cholesterol into pregnenolone, and is kept in check via a 
negative feedback loop by an increased cortisol level. By 
blocking the activity of 17α hydroxylase, cortisol production 
is diminished and the negative feedback effect on ACTH is 
removed. This leads to increased production of ACTH which, 
in turn, stimulates production of precursors above the 17α 
hydroxylase level. One of these precursors is corticosterone 
which is only a weak inhibitor of ACTH; high levels of cor-
ticosterone are required to inhibit the production of ACTH. 
The increased production of corticosterone leads to fluid 
retention, hypokalemia, and hypertension. These effects can 
be prevented by concomitant administration of low doses of 
prednisone, corticosterone, or dexamethasone.
CYP17 inhibition in prostate cancer
Inhibition of adrenal androgen steroid synthesis via CYP17 in 
men with prostate cancer has led to clinical antitumor 
responses. Use of ketoconazole and aminoglutethamide has 
been associated with prostate-specific antigen declines and 
measurable disease responses in some CRPC patients; these 
agents also have significant toxicity and are not associated 
with a survival benefit.16 However, these data suggested 
that a better inhibitor with less toxicity and more durable 
efficacy might lead to significant clinical benefit in CRPC. 
Abiraterone acetate was identified to be a potent and selective 
irreversible inhibitor of CYP17. Preclinical studies with 
abiraterone demonstrated reduction in androgen production 
downstream of CYP17 which resulted in decreased weight 
of the ventral prostate, testis, and seminal vesicles in mice.17 
The first-in-human studies demonstrated a dose of 800 mg 
once daily to be effective in suppressing testosterone to below 
detectable levels in humans and also provided a preliminary 
insight into its safety profile.18
Phase I studies
Based on the clinical data suggesting the importance of 
CYP17 in androgen synthesis and the activity of abiraterone 
in preclinical models, Phase I studies of this agent were 
initiated. One study evaluated 21 CRPC patients who received 
escalating doses of abiraterone from 250 mg to 2000 mg. 
Antitumor activity was noted at all levels. However, due to 
a plateau effect in pharmacokinetics noted at 1000 mg, this 
dose was selected for further drug development. Decreases in 
testosterone, estradiol, and androgenic steroids downstream 
of CYP17 blockade were noted in all patients, as well as an 
increase in ACTH and steroids upstream of the blockade. 
Declines in prostate-specific antigen of $30%, $50%, 
and $90% were observed in 14 (66%), 12 (57%), and six 
(29%) patients, respectively. A reduction in pain medication 
requirement and radiologic regression were noted in many 
patients. Adverse effects, mainly fluid retention, hypokalemia, 
and lower extremity edema, were easily reversed with epler-
enone (a mineralocorticoid receptor antagonist). Interestingly, 
six patients in the study had an ERG rearrangement. Five of 
these patients responded well to treatment with abiraterone. 
ERG rearrangements can potentially be used in the future as 
a predictor of favorable outcome in response to abiraterone.19 
This study also looked at the use of dexamethasone to test 
the hypothesis that pot  ential resistance to abiraterone could 
be overcome with steroids by inhibiting ACTH and also 
to prevent upstream steroid production from stimulating a 
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Figure 1 Schematic diagram of steroid synthesis. 
Note: Role of CYP17 at key enzymatic steps and its inhibition by abiraterone acetate.
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promiscuous androgen receptor. During the study, four of 
15 (26%) patients did respond to the addition of dexametha-
sone and became resensitized to abiraterone.19
Another Phase I study of 33 chemotherapy-naïve CRPC 
patients, some of who had previously been treated with 
ketoconazole, evaluated the response to escalating doses of 
abiraterone acetate. Eighteen patients (55%) demonstrated a 
prostate-specific antigen decline of $50%. In addition, this 
study demonstrated that abiraterone could overcome keto-
conazole resistance, since 47% of ketoconazole-pretreated 
patients experienced $50% prostate-specific antigen 
declines, and confirmed the 1000 mg daily dose of abiraterone 
acetate for future studies.20
Phase II studies
Two Phase II studies evaluated the anticancer activity and 
safety of abiraterone. One study enrolled 42 chemotherapy-
naïve CRPC patients with a primary endpoint of a $50% 
decline in prostate-specific antigen. A $50% decline in 
  prostate-specific antigen was observed in 28 (67%) patients 
and a $90% decline of prostate-specific antigen was 
observed in eight (19%) patients. Addition of dexametha-
sone to abiraterone at disease progression was noted to lead 
to confirmed secondary $50% prostate-specific antigen 
declines in 33% of patients. Twenty-four patients had mea-
surable disease according to the Response Evaluation Criteria 
in Solid Tumors, and nine patients (37.5%) showed tumor 
regression on computed tomography scans.21
Until recently, patients previously treated with docetaxel 
had few proven treatment options. A Phase II trial tested the 
efficacy of abiraterone monotherapy in 47 CRPC patients 
previously treated with docetaxel. Prostate-specific antigen 
declines of $30%, $50%, and $90% were seen in 68%, 
51%, and 15% of patients, respectively. This study dem-
onstrated that abiraterone has potent antitumor activity in 
patients treated with docetaxel.22 The common side effects 
noted in this study were hypokalemia, hypertension, and fluid 
retention, which were able to be managed with eplerenone.
To overcome these side effects of secondary hyper-
aldosteronism associated with single-agent abirater-
one, low-dose prednisone was added to abiraterone in 
another study of docetaxel-pretreated CRPC. Fifty-eight 
men were enrolled, of whom 27 had prior exposure to 
ketoconazole. Twenty-two patients (36%) experienced 
a $50% decline in prostate-specific antigen which also 
included 14 (45%) of 31 ketoconazole-naïve and seven (26%) 
of 27 ketoco  nazole-pretreated patients.23 While similar side 
effects were noted in this study compared with abiraterone 
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studies without prednisone, the incidence of these side effects 
was significantly reduced.
Another Phase II study assessed the efficacy of 
ab  iraterone in CRPC patients naïve to both chemotherapy 
and ketoconazole. Along with prostate-specific antigen, serial 
changes in bone scan lesions were used to assess the disease 
process. The study not only demonstrated the efficacy of 
abiraterone in CRPC, but also highlighted the discordance of 
bone scan intensity and disease progression. The study was 
designed to include 33 CRPC patients who received 1000 mg 
of abiraterone daily along with 5 mg of prednisone twice daily 
in 28-day cycles. Bone scan “flare” was defined as disease 
progression by a radiologist after 3 months of treatment in the 
context of a $50% decline in prostate-specific antigen, with 
scan improvement or stability after an additional 3 months. 
Median time on therapy was 63 weeks and time to prostate-
specific antigen progression was 16.3 months. Twenty-two of 
the 33 patients (67%) showed a decline in prostate-specific 
antigen of $50% within 12 months. Overall, 26 of 33 patients 
(79%) showed a $50% decline in prostate-specific antigen. 
Twelve of 23 (52%) patients demonstrated a bone scan flare, 
of which 11 showed eventual improvement in bone scan over 
time. The side effects noted in the study were mainly grade 
1.24 The results of the above mentioned studies are summa-
rized in Table 1 along with the Phase III study results.
Despite significant antitumor activity demonstrated by 
abiraterone, as evidenced by a declining prostate-specific 
antigen level, it was noted that the decline was short-lived, and 
the prostate-specific antigen ultimately increased. This could 
potentially be explained by the fact that although abiraterone 
blocks androgen synthesis at the CYP17 level, androgens 
upstream continue to accumulate and can potentially stimulate 
an altered androgen receptor. This was demonstrated by Zhao 
et al in their study of prostate cancer cells in a patient resistant 
to androgen ablation therapy. The androgen receptor contained a 
double mutation which had high affinity for cortisol/cortisone, 
leading to increased prostate-specific antigen production. These 
sorts of alterations lead to the possibility that increased hor-
mone levels upstream of CYP17 blockade may cause prostate-
specific antigen rises after an initial decline. However, more 
work needs to be done to explore this theory further.25
Phase III studies
Based on the encouraging results of the above studies, 
a Phase III trial was initiated in April 2008 which random-
ized 1195 patients with docetaxel-refractory CRPC to either 
abiraterone or placebo in a 2:1 fashion; both arms received 
prednisone 5 mg twice daily. Based on the recommendations 
of an independent data monitoring committee, the study was 
unblinded on August 20, 2010. At this point, the abiraterone-
treated patients had received a median of eight 28-day cycles, 
and the patients in the placebo arm had received a median 
four 28-day cycles. The study demonstrated a median overall 
survival in the abiraterone-treated arm of 14.8 months com-
pared with 10.9 months in the placebo arm (hazards ratio 
0.646, 95% confidence interval: 0.54–0.77; P , 0.0001). 
The abiraterone arm also yielded superior outcomes in time 
to prostate-specific antigen progression (10.2 months versus 
6.6 months, P , 0.0001), radiographic progression-free 
survival (5.6 months versus 3.6 months P , 0.0001), and 
prostate-specific antigen declines $50% (confirmed, 29.1% 
versus 5.5%, P , 0.0001).26 Based on these data, abiraterone 
acetate was approved by the Food and Drug Administration 
on April 28, 2011. The recommended dose is 1000 mg daily 
along with prednisone 5 mg twice daily. The most common 
adverse effects seen on abiraterone therapy were joint dis-
comfort, hypertension, and hypokalemia.
Ongoing studies
Currently, a Phase II study is looking at the addition of 
dutasteride to abiraterone in metastatic CRPC. This study 
will be looking at mechanisms of androgen receptor resis-
tance to abiraterone, as well as the effects of a combination 
of abiraterone/dutasteride on levels of testosterone, dihy-
drotestosterone at baseline, and progression. It will also look 
at the effect of the combination on the toxicity profile and 
duration of prostate-specific antigen response. Another trial 
is underway looking at the addition of sunitinib or dasatinib 
to abiraterone acetate for the treatment of prostate cancer. 
Ad  ditional Phase III studies are investigating abiraterone in 
other contexts. One trial is currently looking at the compari-
son of abiraterone plus prednisone versus placebo and pred-
nisone in asymptomatic or mildly symptomatic metastatic 
CRPC who have not received chemotherapy.
Conclusion
The recent Food and Drug Administration approvals of cabazi-
taxel, sipuleucel-T, and abiraterone acetate for the treatment of 
CRPC have provided clinicians with much needed additional 
treatment options for prostate cancer. The exact sequencing 
of these agents in CRPC treatment requires further evaluation. 
Both cabazitaxel and abiraterone have shown survival benefits 
in docetaxel-pretreated patients. The appropriate sequencing 
of abiraterone and cabazitaxel is not known at this time. Given 
the toxicity profiles of both agents, patients with significant 
docetaxel-associated toxicity might benefit from a break from 
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cytotoxic chemotherapy and be guided towards abiraterone. 
Other patients with disease progression but excellent perfor-
mance status and more modest chemotherapy-associated toxic-
ity might be best served by further highly active chemotherapy. 
The recent approval of abiraterone and its proven efficacy in 
docetaxel-pretreated patients provides yet another treatment 
option for this patient population. Ongoing trials will evaluate 
whether abiraterone leads to a survival benefit in patients with 
chemotherapy-naïve CRPC. The activity of abiraterone in 
prostate cancer suggests that it should also be explored as part 
of adjunctive hormonal therapy in localized prostate cancer 
to improve cure rates in high-risk patients. Localized prostate 
cancer trials are just beginning to be launched and will take 
many years to demonstrate benefits.
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